Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#2266 Prognostic Value of the Different Pre-Treatment Biomarkers for Patients with Neuroendocrine Tumors

Introduction: Several inflammatory response materials could be used for prediction of prognosis in cancer patients. The neutrophil lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), thrombocytosis (the platelets number >400*103/mm3) have been introduced for prognostic scoring system in various cancers.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: croitoru A

Authors: Grigorescu R, Croitoru A, Stanel I, Gheorghe C, Grama I,

Keywords: prognostic factors, survival,

#1781 Clinical Characteristics and Treatment Outcome of Advanced G3 Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)- A Retrospective Analysis

Introduction: Advanced poorly differentiated GEP-NEC are uncommon neoplasms and treated mainly with platinum-based chemotherapy associated with etoposide.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Croitoru A

Authors: Grigorescu R, Stanel I, Gramaticu I, Dinu I, Buica F,

Keywords: GEP-NEC, chemotherapy, prognostic factors,

#1764 Use of Tyrosine-Kinase Inhibitors in Medullary Thyroid Carcinoma: An Institutional Experience

Introduction: Medullary thyroid cancer (MTC) comprises 4% of thyroid tumors. 7-23% of patients (pts) have metastases at diagnosis. In some cases metastatic disease follows an indolent course, and in others it progresses rapidly, requiring systemic treatment. Tyrosine-kinase inhibitors (TKI) have demonstrated a median progression-free survival (PFS) of 11 months.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Luca R

Authors: Luca R, O'Connor J, Falco A, Do Pico F, Tsou F,

Keywords: TNE, TKI,